Neoplasms by Site Recruiting Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0030096 (Neoplasms by Site)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04556071Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian CancerTreatment